1. Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation.
- Author
-
Verma A, Hawes CE, Lakshmanappa YS, Roh JW, Schmidt BA, Dutra J, Louie W, Liu H, Ma ZM, Watanabe JK, Usachenko JL, Immareddy R, Sammak RL, Pollard R, Reader JR, Olstad KJ, Coffey LL, Kozlowski PA, Hartigan-O'Connor DJ, Nussenzweig M, Van Rompay KKA, Morrison JH, and Iyer SS
- Subjects
- Aging immunology, Animals, COVID-19 cerebrospinal fluid, COVID-19 complications, COVID-19 immunology, Diabetes Complications immunology, Diabetes Complications virology, Diabetes Mellitus, Experimental complications, Diabetes Mellitus, Experimental immunology, Female, Humans, Lymphocyte Activation, Macaca mulatta, Male, Neuritis immunology, Neuritis prevention & control, Pre-Exposure Prophylaxis, T-Lymphocytes immunology, Virus Replication immunology, Antibodies, Monoclonal therapeutic use, COVID-19 prevention & control, SARS-CoV-2 immunology
- Abstract
Anti-viral monoclonal antibody (mAb) treatments may provide immediate but short-term immunity from coronavirus disease 2019 (COVID-19) in high-risk populations, such as people with diabetes and the elderly; however, data on their efficacy in these populations are limited. We demonstrate that prophylactic mAb treatment blocks viral replication in both the upper and lower respiratory tracts in aged, type 2 diabetic rhesus macaques. mAb infusion dramatically curtails severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-mediated stimulation of interferon-induced chemokines and T cell activation, significantly reducing development of interstitial pneumonia. Furthermore, mAb infusion significantly dampens the greater than 3-fold increase in SARS-CoV-2-induced effector CD4 T cell influx into the cerebrospinal fluid. Our data show that neutralizing mAbs administered preventatively to high-risk populations may mitigate the adverse inflammatory consequences of SARS-CoV-2 exposure., Competing Interests: Declaration of interests The authors declare no competing interests., (Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF